

Antibody Drug Conjugate-Asia Pacific Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/A38CEC5AC2FMEN.html

Date: February 2018 Pages: 145 Price: US\$ 3,480.00 (Single User License) ID: A38CEC5AC2FMEN

Abstracts

Report Summary

Antibody Drug Conjugate-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody Drug Conjugate industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Antibody Drug Conjugate 2013-2017, and development forecast 2018-2023 Main market players of Antibody Drug Conjugate in Asia Pacific, with company and product introduction, position in the Antibody Drug Conjugate market Market status and development trend of Antibody Drug Conjugate by types and applications

Cost and profit status of Antibody Drug Conjugate, and marketing status Market growth drivers and challenges

The report segments the Asia Pacific Antibody Drug Conjugate market as:

Asia Pacific Antibody Drug Conjugate Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China Japan Korea India



Southeast Asia

Australia

Asia Pacific Antibody Drug Conjugate Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Adcetris Kadcyl Other

Asia Pacific Antibody Drug Conjugate Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmaceutical Company Research Institutions

Asia Pacific Antibody Drug Conjugate Market: Players Segment Analysis (Company and Product introduction, Antibody Drug Conjugate Sales Volume, Revenue, Price and Gross Margin):

Seattle Genetics/Takeda Roche ImmunoGen Immunomedics Pfizer Celldex Therapeutics Millennium Pharmaceuticals Bayer HealthCare Mersana Therapeutics Heidelberg Pharma Oxford BioTherapeutics Takeda Pharmaceutical Company Limited

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF ANTIBODY DRUG CONJUGATE

- 1.1 Definition of Antibody Drug Conjugate in This Report
- 1.2 Commercial Types of Antibody Drug Conjugate
- 1.2.1 Adcetris
- 1.2.2 Kadcyl
- 1.2.3 Other
- 1.3 Downstream Application of Antibody Drug Conjugate
- 1.3.1 Hospital
- 1.3.2 Pharmaceutical Company
- 1.3.3 Research Institutions
- 1.4 Development History of Antibody Drug Conjugate
- 1.5 Market Status and Trend of Antibody Drug Conjugate 2013-2023
- 1.5.1 Asia Pacific Antibody Drug Conjugate Market Status and Trend 2013-2023
- 1.5.2 Regional Antibody Drug Conjugate Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Antibody Drug Conjugate in Asia Pacific 2013-2017
- 2.2 Consumption Market of Antibody Drug Conjugate in Asia Pacific by Regions
- 2.2.1 Consumption Volume of Antibody Drug Conjugate in Asia Pacific by Regions
- 2.2.2 Revenue of Antibody Drug Conjugate in Asia Pacific by Regions
- 2.3 Market Analysis of Antibody Drug Conjugate in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Antibody Drug Conjugate in China 2013-2017
 - 2.3.2 Market Analysis of Antibody Drug Conjugate in Japan 2013-2017
 - 2.3.3 Market Analysis of Antibody Drug Conjugate in Korea 2013-2017
 - 2.3.4 Market Analysis of Antibody Drug Conjugate in India 2013-2017
- 2.3.5 Market Analysis of Antibody Drug Conjugate in Southeast Asia 2013-2017
- 2.3.6 Market Analysis of Antibody Drug Conjugate in Australia 2013-2017

2.4 Market Development Forecast of Antibody Drug Conjugate in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Antibody Drug Conjugate in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of Antibody Drug Conjugate by Regions 2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES



- 3.1 Whole Asia Pacific Market Status by Types
- 3.1.1 Consumption Volume of Antibody Drug Conjugate in Asia Pacific by Types
- 3.1.2 Revenue of Antibody Drug Conjugate in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
- 3.2.1 Market Status by Types in China
- 3.2.2 Market Status by Types in Japan
- 3.2.3 Market Status by Types in Korea
- 3.2.4 Market Status by Types in India
- 3.2.5 Market Status by Types in Southeast Asia
- 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of Antibody Drug Conjugate in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Antibody Drug Conjugate in Asia Pacific by Downstream Industry

4.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Major Countries

- 4.2.1 Demand Volume of Antibody Drug Conjugate by Downstream Industry in China
- 4.2.2 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Japan
- 4.2.3 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Korea
- 4.2.4 Demand Volume of Antibody Drug Conjugate by Downstream Industry in India

4.2.5 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Southeast Asia

4.2.6 Demand Volume of Antibody Drug Conjugate by Downstream Industry in Australia

4.3 Market Forecast of Antibody Drug Conjugate in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY DRUG CONJUGATE

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Antibody Drug Conjugate Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTIBODY DRUG CONJUGATE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC



- 6.1 Sales Volume of Antibody Drug Conjugate in Asia Pacific by Major Players
- 6.2 Revenue of Antibody Drug Conjugate in Asia Pacific by Major Players
- 6.3 Basic Information of Antibody Drug Conjugate by Major Players

6.3.1 Headquarters Location and Established Time of Antibody Drug Conjugate Major Players

6.3.2 Employees and Revenue Level of Antibody Drug Conjugate Major Players6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 ANTIBODY DRUG CONJUGATE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Seattle Genetics/Takeda
- 7.1.1 Company profile
- 7.1.2 Representative Antibody Drug Conjugate Product
- 7.1.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Seattle

Genetics/Takeda

7.2 Roche

7.2.1 Company profile

- 7.2.2 Representative Antibody Drug Conjugate Product
- 7.2.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Roche

7.3 ImmunoGen

- 7.3.1 Company profile
- 7.3.2 Representative Antibody Drug Conjugate Product
- 7.3.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of ImmunoGen

7.4 Immunomedics

- 7.4.1 Company profile
- 7.4.2 Representative Antibody Drug Conjugate Product
- 7.4.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Immunomedics

7.5 Pfizer

- 7.5.1 Company profile
- 7.5.2 Representative Antibody Drug Conjugate Product
- 7.5.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Pfizer
- 7.6 Celldex Therapeutics



- 7.6.1 Company profile
- 7.6.2 Representative Antibody Drug Conjugate Product

7.6.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Celldex

Therapeutics

- 7.7 Millennium Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative Antibody Drug Conjugate Product
- 7.7.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Millennium Pharmaceuticals
- 7.8 Bayer HealthCare
- 7.8.1 Company profile
- 7.8.2 Representative Antibody Drug Conjugate Product
- 7.8.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Bayer

HealthCare

- 7.9 Mersana Therapeutics
 - 7.9.1 Company profile
 - 7.9.2 Representative Antibody Drug Conjugate Product
- 7.9.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Mersana

Therapeutics

- 7.10 Heidelberg Pharma
 - 7.10.1 Company profile
 - 7.10.2 Representative Antibody Drug Conjugate Product
- 7.10.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of

Heidelberg Pharma

- 7.11 Oxford BioTherapeutics
 - 7.11.1 Company profile
 - 7.11.2 Representative Antibody Drug Conjugate Product
- 7.11.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Oxford BioTherapeutics
- 7.12 Takeda Pharmaceutical Company Limited
- 7.12.1 Company profile
- 7.12.2 Representative Antibody Drug Conjugate Product

7.12.3 Antibody Drug Conjugate Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY DRUG CONJUGATE

8.1 Industry Chain of Antibody Drug Conjugate



- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY DRUG CONJUGATE

- 9.1 Cost Structure Analysis of Antibody Drug Conjugate
- 9.2 Raw Materials Cost Analysis of Antibody Drug Conjugate
- 9.3 Labor Cost Analysis of Antibody Drug Conjugate
- 9.4 Manufacturing Expenses Analysis of Antibody Drug Conjugate

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY DRUG CONJUGATE

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Antibody Drug Conjugate-Asia Pacific Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/A38CEC5AC2FMEN.html</u>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A38CEC5AC2FMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970